Latest Share Chat

Astrazeneca Share News (AZN)

Astrazeneca Information

Buy AZN Shares
Add AZN to Watchlist
Add AZN to Alert

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 12,102.00

Bid: 12,098.00

Ask: 12,102.00

Change: 52.00 (0.43%)

Spread: 4.00 (0.033%)

Open: 11,966.00

High: 12,124.00

Low: 11,966.00

Prev. Close: 12,050.00

Last checked at -

Leave vote would have limited impact on FTSE, says SpreadCo analyst

Tue, 21st Jun 2016 13:12

(ShareCast News) - Although consensus is that the FTSE 100 will rally if voters in the UK opt to remain in the European Union on Thursday and sell off on a Leave vote, the overall impact of an exit on London stocks may be limited, said SpreadCo analyst David Morrison."The damage to the FTSE100 as a whole may be limited. Not only due to its weighting towards internationally-facing corporations, but also because any weakness in sterling will make these companies more competitive and thereby boost earnings."Of course there will be individual winners and losers and ultimately the overall effect on the FTSE100 could be limited due to its constituents having a heavy international (around 70%) exposure."He pointed out that the share prices of big multinationals that derive a large chunk of their revenue and earnings from outside the EU are likely to benefit from a Leave vote."Quite simply, money will flow from stocks with direct exposure to Europe to those more internationally facing," he argued.Pharmaceuticals such as AstraZeneca, GlaxoSmithKline and Shire, oil majors and miners are likely to benefit as could companies with low exposure to the EU such as Centrica and Prudential.However, airlines and tour operators may suffer a bout of selling first and questions asked later. Morrison highlighted EasyJet and Carnival as being at risk.Meanwhile, pure domestic players such as housebuilders and banks like Lloyds are also likely to suffer.As for the pound, Morrison said consensus was that GBP/USD would fall to between 1.1000 and 1.3000 in the event of a Leave vote. "Let's call it 1.2000 and let's assume cable is trading around 1.4000 ahead of the vote. That implies a decline of around 14%."In the event of a Remain vote, cable could surge to around 1.5000 initially. "If we again use 1.4000 as our pre-vote starting point, we're looking at 1.2000 on the downside and maybe 1.5000 to the up."

More News

12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Latest Share Chat

Astrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Leave vote would have limited impact on FTSE, says SpreadCo analyst

Login to your account

Quickpicks are a member only feature

Login to your account